Midazolam and propofol used alone or sequentially for long-term sedation in critically ill, mechanically ventilated patients: a prospective, randomized study

Table 1 Baseline demographic data

Variable	Group M (n = 43)	Group P (n = 42)	Group M-P (n = 39)	P value
Age (years)	54.8 ± 13.6	55.9 ± 18.0	53.2 ± 16.8	0.75
Weight (kg)	60.1 ± 10.2	58.4 ± 9.8	59.6 ± 9.2	0.71
Gender (male/female)	26/17	24/18	24/15	0.91
SOFA score at enrollment	7.9 ± 2.5	8.3 ± 2.0	9.0 ± 2.0	0.10
SAS score at enrollment	5.6 ± 0.9	5.5 ± 0.8	5.4 ± 0.8	0.77
Diagnosis at ICU admission
Sepsis	6	6	5	1.00
COPD/CHF	3	4	3	0.92
Pneumonia	6	8	7	0.83
Pancreatitis	8	6	5	0.82
Trauma	14	10	12	0.65
Postoperative
Vascular surgery	1	2	3	0.44
Liver transplant	1	1	0	1.00
Abdominal surgery	4	5	4	0.88

Values are expressed as mean ± standard deviation. CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; group M, midazolam group; group M-P, midazolam and propofol group; group P, propofol group; SAS, Riker sedation–agitation scale at ICU admission; SOFA, Sequential Organ Failure Assessment at ICU admission. Normally distributed data were compared using one-way analysis of variance. The Student–Newman–Keuls test was used for post hoc multiple comparisons. Nominal data comparisons were based on either the chi-square test or Fisher's exact test.

ISSN: 1364-8535